Alphamab Oncology (STU:3NK) EPS (Basic) : €0.02 (TTM As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology EPS (Basic)?

Alphamab Oncology's basic earnings per share (Basic EPS) for the six months ended in Jun. 2024 was €-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was €0.02.

Alphamab Oncology's EPS (Diluted) for the six months ended in Jun. 2024 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €0.02.

Alphamab Oncology's EPS without NRI for the six months ended in Jun. 2024 was €-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was 0.02.

During the past 3 years, the average EPS without NRI Growth Rate was 24.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Alphamab Oncology's highest 3-Year average EPS without NRI Growth Rate was 39.30% per year. The lowest was -132.60% per year. And the median was -25.75% per year.

Alphamab Oncology EPS (Basic) Historical Data

The historical data trend for Alphamab Oncology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology EPS (Basic) Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-0.06

-0.05

-0.03

0.02

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	Get a 7-Day Free Trial										-0.03	-0.01	-0.02	-0.01	0.03

Alphamab Oncology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Alphamab Oncology's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-27.046	-	0)	/	959.899
	=	-0.03

Alphamab Oncology's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5.749	-	0)	/	962.809
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.02

Alphamab Oncology (STU:3NK) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Alphamab Oncology EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

09966:Hong Kong

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Alphamab Oncology Headlines

No Headlines